CJC-1295 / Ipamorelin
Growth-hormone signaling research
Stimulating the body's release of growth hormone is the research focus behind CJC-1295 and Ipamorelin. The individual compounds have been studied for their effects on hormone signaling. This does not establish that the blend improves muscle growth, sleep or recovery, and its exact CJC variant remains unconfirmed.
$99 USD
Indicative price, not an active offer. Quantity per vial is not yet confirmed.
Not accepting orders
This is a proposed research listing. Supplier terms, material specifications and lot documents must be established before commercial launch.
Product documentation
Lot-specific COA, final specification and safety documentation are not yet published.
Check CJC-1295 / Ipamorelin document statusFor laboratory research only. Not for human or veterinary use.
What is being studied?
Published CJC-1295 research includes a study of a long-acting GHRH analog in healthy adults. Ipamorelin has separately been characterized as a growth-hormone secretagogue. These are distinct research records. They do not establish the effects of an unspecified CJC-1295 / Ipamorelin blend.
Research background: Teichman et al. (2006): long-acting CJC-1295 in healthy adults; Raun et al. (1998): pharmacological characterization of Ipamorelin.
What the evidence does not establish
The CJC variant is not yet selected. Evidence for the long-acting material in the cited study must not be assigned to a product simply called CJC without confirming its structure. Separate studies also do not demonstrate synergy or validate the proposed combination.
Define the material first.
Confirm the exact CJC sequence and DAC status, the Ipamorelin specification, both quantities and the blend ratio. Require lot documentation that makes clear which component each analytical result describes.
Before comparing price, make sure the quantities and specifications being compared are equivalent. A publication describes its study material; a supplier report describes a particular tested sample. Those are different kinds of evidence.
Read the documentation checklistQuestions about CJC-1295 / Ipamorelin
Does this listing use CJC with DAC?
That has not been confirmed. We will not describe the listing as DAC or non-DAC until the supplier's exact specification is established.
Is the blend covered by the two references?
The references concern the individual research compounds. They are not evidence that this particular blend has been studied or tested.
Sources and scope
- Teichman et al. (2006): long-acting CJC-1295 in healthy adults
- Raun et al. (1998): pharmacological characterization of Ipamorelin
Source records checked September 11, 2026. This is an introductory research summary, not a systematic review, medical recommendation or lot certificate. The selection is not exhaustive. Independent scientific review and final supplier documentation remain pending.
Compare the research area